Stock GTBP GT BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

GT Biopharma, Inc. Stock

Equities

GTBP

US36254L3087

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
3.75 USD -2.85% Intraday chart for GT Biopharma, Inc. +1.90% -50.98%
May. 21 Top Midday Decliners MT
May. 21 GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants MT

Financials (USD)

Sales 2022 - Sales 2023 - Capitalization 10.56M
Net income 2022 -20M Net income 2023 -7M EV / Sales 2022 -
Net cash position 2022 16.33M Net cash position 2023 13.91M EV / Sales 2023 -
P/E ratio 2022
-1.35 x
P/E ratio 2023
-1.36 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 89.34%
More Fundamentals * Assessed data

Chart GT Biopharma, Inc.

Dynamic Chart

Latest news about GT Biopharma, Inc.

Top Midday Decliners MT
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants MT
Top Premarket Gainers MT
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall MT
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia CI
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Index CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Growth Index CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Growth Index CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Index CI
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news

Analyst Recommendations on GT Biopharma, Inc.

EF Hutton Starts GT Biopharma at Hold With $2 Price Target MT
HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating MT
Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9 MT
B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
GT BIOPHARMA : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating MT
More recommendations

Press releases GT Biopharma, Inc.

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules AQ
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update AQ
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results AQ
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split AQ
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS AQ
More press releases

News in other languages on GT Biopharma, Inc.

Caterpillar deja París, el cacao está menos caliente
Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud
More news

Quotes and Performance

1 day-2.85%
1 week+1.90%
1 month+18.30%
3 months-14.77%
6 months-42.40%
Current year-50.98%
More quotes

Highs and lows

1 week
3.31
Extreme 3.31
3.89
1 month
3.02
Extreme 3.02
10.66
Current year
2.95
Extreme 2.9539
10.66
1 year
2.95
Extreme 2.9539
16.11
3 years
2.95
Extreme 2.9539
591.99
5 years
2.95
Extreme 2.9539
591.99
10 years
2.95
Extreme 2.9539
1 000 000.00
More quotes

Managers and Directors - GT Biopharma, Inc.

Managers TitleAgeSince
Michael Breen CEO
 Chief Executive Officer 61 21-01-12
Manu Ohri DFI
 Director of Finance/CFO 68 22-02-17
Jeffrey Miller PRN
 Corporate Officer/Principal - 22-12-13
Members of the board TitleAgeSince
Charles Casamento BRD
 Director/Board Member 78 23-04-30
Bruce Wendel BRD
 Director/Board Member 70 20-11-10
Rajesh Shrotriya BRD
 Director/Board Member 79 21-01-12
More insiders

Quotes

Date Price Change Volume
24-05-31 3.75 -2.85% 17,663
24-05-30 3.86 +9.35% 67,975
24-05-29 3.53 -.--% 86,260
24-05-28 3.53 -4.08% 119,573
24-05-24 3.68 -5.64% 147,908

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes

Company Profile

GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system. The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Sector
Pharmaceuticals
Calendar
2024-06-25 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GT BIOPHARMA, INC. Stock GT Biopharma, Inc.
-50.98% 8.09M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GTBP Stock